Vigne P, Frelin C, Audinot M, Borsotto M, Cragoe E J, Lazdunski M
EMBO J. 1984 Nov;3(11):2647-51. doi: 10.1002/j.1460-2075.1984.tb02188.x.
The interaction of amiloride and several amiloride derivatives with the Na+/H+ exchange system in Madin-Darby canine kidney cells and in rabbit renal microvillus membrane vesicles was studied from 22Na+ uptake experiments. On both types of preparation, the order of potency of the different molecules tested is: ethylisopropylamiloride greater than ethylpropylamiloride (EPA) greater than amiloride greater than benzamil. 3H-labelled EPA was prepared and used to titrate amiloride binding sites in solubilized microvillus membranes. Kinetics experiments, equilibrium binding studies and competition experiments between [3H]EPA and unlabelled EPA indicate that EPA recognizes a single family of binding sites with a Kd value of 45 nM and a maximum binding capacity of 2 pmol/mg of protein. The order of potency of different amiloride analogs tested in [3H]EPA competition experiments is identical to that found for the inhibition of 22Na+ uptake by the Na+/H+ exchange system, suggesting that [3H]EPA binding sites are associated with the Na+/H+ exchange system. [3H]EPA binding sites are pharmacologically distinct from those of [3H]benzamil and [3H]bumetanide in kidney membranes.
通过²²Na⁺摄取实验研究了氨氯吡脒及其几种衍生物与麦迪逊-达比犬肾细胞和兔肾微绒毛膜囊泡中Na⁺/H⁺交换系统的相互作用。在这两种制剂上,所测试的不同分子的效力顺序为:乙基异丙基氨氯吡脒大于乙基丙基氨氯吡脒(EPA)大于氨氯吡脒大于苄氨氯吡脒。制备了³H标记的EPA并用于滴定溶解的微绒毛膜中的氨氯吡脒结合位点。动力学实验、平衡结合研究以及[³H]EPA与未标记EPA之间的竞争实验表明,EPA识别单一的结合位点家族,其Kd值为45 nM,最大结合容量为2 pmol/mg蛋白质。在[³H]EPA竞争实验中测试的不同氨氯吡脒类似物的效力顺序与Na⁺/H⁺交换系统对²²Na⁺摄取抑制的顺序相同,这表明[³H]EPA结合位点与Na⁺/H⁺交换系统相关。[³H]EPA结合位点在药理学上与肾膜中的[³H]苄氨氯吡脒和[³H]布美他尼的结合位点不同。